Polysaccharide Diphtheria Toxoid Conjugate Vaccine Articles

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra

3 December 2012

US FDA approves Sanofi-Pasteur’s Menactra for infants and extends GSK’s Lamictal use; Merck/Sanofi combo vaccine moves into Ph III

26 April 2011

Regulatory briefs: Shire’s Vpriv cleared in Europe; Menactra for toddlers; Updates for Novartis and Roche

27 August 2010

US watchdog CREW calls on FTC to investigate if doctors are giving patients the best - or best priced - vaccines

8 July 2010

Novartis vacc beats Menactra in Ph III trials

12 May 2008

Sanofi-Aventis 2007 profits rise a modest 1%; sales impacted by exchange rates

18 February 2008

New data suggest Novartis' Menveo could be first four-strain infant meningitis vacc

21 January 2008

FDA expands age range for Menactra

29 October 2007

Sanofi-Aventis beats expectations with 1st-qtr adjusted EPS rising 53%

15 May 2006

Sanofi-Aventis's Menactra linked to three cases of GB syndrome

17 April 2006

Sanofi-Aventis sales slow on competition

6 February 2006

US volume Rx sales rise 8.3% in 2004

21 February 2005

FDA approves Sanofi Pasteur's Menactra

24 January 2005

Good news for Sanofi-Aventis' Menactra

4 October 2004

Aventis highlights its late-stage pipeline to justify its stand-alone strategy

16 February 2004

Aventis sells pharma plant to Famar

19 January 2004

Aventis submits BLA for its Menactra vacc

5 January 2004

Aventis says human vaccines business will maintain double-digit growth

6 October 2003

Aventis updates on near-term pipeline

10 February 2003

Showing 1-19 of 19 articles

Go to beginningPrevious
  • 1
NextGo to end